Similar articles

• Combination lipid therapy in type 2 diabetes.

  Perkins WJ Jr. Perkins WJ Jr. N Engl J Med. 2010 Aug 12;363(7):694; author reply 694-5. doi: 10.1056/NEJMc1006407. N Engl J Med. 2010. PMID: 20842773 No abstract available.
• [Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes].

  Radermecker RP, Scheen AJ. Radermecker RP, et al. Rev Med Liege. 2005 Dec;60(12):957-61. Rev Med Liege. 2005. PMID: 16457397 Clinical Trial. French.
• Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

  Scott R, Best J, Forder P, Taskinen MR, Simes J, Barter P, Keech A; FIELD Study Investigators. Scott R, et al. Cardiovasc Diabetol. 2005 Aug 22;4:13. doi: 10.1186/1475-2840-4-13. Cardiovasc Diabetol. 2005. PMID: 16111499 Free PMC article. Clinical Trial.
• Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

  Keating GM, Ormrod D. Keating GM, et al. Drugs. 2002;62(13):1909-44. doi: 10.2165/00003495-200262130-00013. Drugs. 2002. PMID: 12215067 Review.
• More clinical lessons from the FIELD study.

  Fazio S. Fazio S. Cardiovasc Drugs Ther. 2009 Jun;23(3):235-41. doi: 10.1007/s10557-008-6160-5. Cardiovasc Drugs Ther. 2009. PMID: 19160032 Review.